Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson Says Fiscal Q2 Revenues Grow 6 Percent As R&D Spending Surges and Profits Fall

NEW YORK, April 26 (GenomeWeb News) - Becton Dickinson today said that total revenues for its fiscal second quarter increased 6.1 percent as R&D spending surged 96 percent and profits declined.


Total receipts for the three months ended March 31 increased to $1.45 billion from $1.37 billion year over year. Revenue from the BD Biosciences unit grew 7.7 percent to $219 million year over year, the second-highest growth this period from among the company's three divisions.


R&D spending increased to $129 million from $66 million in the year-ago period, the company said.


Profits declined to $154 million, or $.63 per share, from $188.2 million, or $.74 per share, year over year.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.